InMed Pharmaceuticals Inc. (INM) vs China SXT Pharmaceuticals, Inc. (SXTC)

InMed Pharmaceuticals Inc. and China SXT Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. InMed Pharmaceuticals Inc. is the larger, with a market value of $7.7M against $3.5M — 2.2× the size. InMed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 19.4% against −54.0%. InMed Pharmaceuticals Inc. has the higher net margin (0.00% vs −255.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, China SXT Pharmaceuticals, Inc. leads on 7 and InMed Pharmaceuticals Inc. on 5.

Valuation

Metric INM SXTC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.00 n/m 2.25
P/B 5.35 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 2.66 12.29
EV/Sales 0.65 (5.94) 2.56
Earnings yield (218.43%) (4,331.13%) (2.99%)
Free cash flow yield (151.13%) 0.00% 0.00%

Profitability

Metric INM SXTC Drug Manufacturers Specialty & Generic median
Gross margin 26.27% 36.69% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (255.16%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (179.09%) 0.00% (0.40%)
Return on assets (139.63%) 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INM SXTC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 19.38% (53.98%) 10.01%
EPS growth (last fiscal year) 62.68% 97.36% —
Revenue growth, 5-year CAGR — (24.94%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INM SXTC Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.03 0.05
Current ratio 1.37 7.94 2.31
Net debt to EBITDA 0.20 3.86 0.85

Dividend

Metric INM SXTC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric INM SXTC Drug Manufacturers Specialty & Generic median
Market cap 7.69m 3.49m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack